File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)

TitleSingle-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)
Authors
Issue Date2009
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/jhh
Citation
Journal Of Human Hypertension, 2009, v. 23 n. 3, p. 196-210 How to Cite?
AbstractThe Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/ atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia. This was a 14-week, open-label study including patients from 27 countries across the Middle East, Asia-Pacific, Africa and Latin America. Eight dosage strengths of single-pill amlodipine/atorvastatin (5/10, 10/10, 5/20, 10/20, 5/40, 10/ 40, 5/80 and 10/80 mg) were titrated to improve blood pressure and lipid control. Blood pressure and lipid goals were determined according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATP III) guidelines, respectively (blood pressure, <140/90 or <130/80 mmHg; low-density lipoprotein cholesterol (LDL-C), <4.1 to <2.6 mmoll-1 (<160 to <100 mgdl-1)). Overall, 1649 patients received study medication. Most patients (91.4%) had ≥1 cardiovascular risk factor (as defined by NCEP ATP III guidelines) in addition to hypertension/dyslipidaemia, and 61.7% had coronary heart disease/risk equivalent. At baseline, mean blood pressure was 146.6/88.3 mmHg and LDL-C was 3.4 mmoll-1 (130.2 mgdl-1). At week 14, 55.2% of patients reached both blood pressure and lipid goals, 61.3% reached blood pressure goal and 87.1% reached lipid goal (34.0% were at lipid goal at baseline). Mean blood pressure reduction was 20.2/11.4 mmHg. For patients who were lipid-lowering drug naive at baseline, mean reduction in LDL-C was 41.0%. Treatment-related adverse events led to the discontinuation of 3.6% of patients. Single-pill amlodipine/ atorvastatin therapy was well tolerated and effective for the reduction of blood pressure and lipids to recommended goals in patients from diverse ethnic backgrounds.
Persistent Identifierhttp://hdl.handle.net/10722/163229
ISSN
2015 Impact Factor: 2.833
2015 SCImago Journal Rankings: 1.167
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorErdine, Sen_US
dc.contributor.authorRo, YMen_US
dc.contributor.authorTse, HFen_US
dc.contributor.authorHowes, LGen_US
dc.contributor.authorAguilar-Salinas, CAen_US
dc.contributor.authorChaves, Hen_US
dc.contributor.authorGuindy, Ren_US
dc.contributor.authorChopra, Pen_US
dc.contributor.authorMoller, RAen_US
dc.contributor.authorSchou, IMen_US
dc.date.accessioned2012-09-05T05:28:59Z-
dc.date.available2012-09-05T05:28:59Z-
dc.date.issued2009en_US
dc.identifier.citationJournal Of Human Hypertension, 2009, v. 23 n. 3, p. 196-210en_US
dc.identifier.issn0950-9240en_US
dc.identifier.urihttp://hdl.handle.net/10722/163229-
dc.description.abstractThe Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/ atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia. This was a 14-week, open-label study including patients from 27 countries across the Middle East, Asia-Pacific, Africa and Latin America. Eight dosage strengths of single-pill amlodipine/atorvastatin (5/10, 10/10, 5/20, 10/20, 5/40, 10/ 40, 5/80 and 10/80 mg) were titrated to improve blood pressure and lipid control. Blood pressure and lipid goals were determined according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATP III) guidelines, respectively (blood pressure, <140/90 or <130/80 mmHg; low-density lipoprotein cholesterol (LDL-C), <4.1 to <2.6 mmoll-1 (<160 to <100 mgdl-1)). Overall, 1649 patients received study medication. Most patients (91.4%) had ≥1 cardiovascular risk factor (as defined by NCEP ATP III guidelines) in addition to hypertension/dyslipidaemia, and 61.7% had coronary heart disease/risk equivalent. At baseline, mean blood pressure was 146.6/88.3 mmHg and LDL-C was 3.4 mmoll-1 (130.2 mgdl-1). At week 14, 55.2% of patients reached both blood pressure and lipid goals, 61.3% reached blood pressure goal and 87.1% reached lipid goal (34.0% were at lipid goal at baseline). Mean blood pressure reduction was 20.2/11.4 mmHg. For patients who were lipid-lowering drug naive at baseline, mean reduction in LDL-C was 41.0%. Treatment-related adverse events led to the discontinuation of 3.6% of patients. Single-pill amlodipine/ atorvastatin therapy was well tolerated and effective for the reduction of blood pressure and lipids to recommended goals in patients from diverse ethnic backgrounds.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/jhhen_US
dc.relation.ispartofJournal of Human Hypertensionen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAgeden_US
dc.subject.meshAmlodipine - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAntihypertensive Agents - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshCardiovascular Diseases - Ethnology - Etiology - Prevention & Controlen_US
dc.subject.meshCholesterol, Ldl - Blooden_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshDyslipidemias - Blood - Complications - Drug Therapy - Ethnologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeptanoic Acids - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshHumansen_US
dc.subject.meshHydroxymethylglutaryl-Coa Reductase Inhibitors - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshHypertension - Complications - Drug Therapy - Ethnology - Physiopathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPractice Guidelines As Topicen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshPyrroles - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleSingle-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)en_US
dc.typeArticleen_US
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/jhh.2008.114en_US
dc.identifier.pmid18800143-
dc.identifier.scopuseid_2-s2.0-60649115839en_US
dc.identifier.hkuros160264-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-60649115839&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume23en_US
dc.identifier.issue3en_US
dc.identifier.spage196en_US
dc.identifier.epage210en_US
dc.identifier.isiWOS:000263316500007-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridErdine, S=7005834615en_US
dc.identifier.scopusauthoridRo, YM=36972570100en_US
dc.identifier.scopusauthoridTse, HF=7006070805en_US
dc.identifier.scopusauthoridHowes, LG=34874943700en_US
dc.identifier.scopusauthoridAguilarSalinas, CA=7006016440en_US
dc.identifier.scopusauthoridChaves, H=6701345627en_US
dc.identifier.scopusauthoridGuindy, R=6506962661en_US
dc.identifier.scopusauthoridChopra, P=7102119265en_US
dc.identifier.scopusauthoridMoller, RA=7004451721en_US
dc.identifier.scopusauthoridSchou, IM=6602332525en_US
dc.identifier.citeulike3292790-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats